Concepts (124)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Skin Neoplasms | 7 | 2022 | 405 | 1.180 |
Why?
|
| Dermatologic Surgical Procedures | 4 | 2019 | 35 | 1.080 |
Why?
|
| Lymphoma, Follicular | 1 | 2022 | 18 | 0.730 |
Why?
|
| Hemostasis | 1 | 2022 | 19 | 0.720 |
Why?
|
| Nose Neoplasms | 2 | 2012 | 17 | 0.590 |
Why?
|
| Mohs Surgery | 4 | 2016 | 53 | 0.520 |
Why?
|
| Surgical Flaps | 4 | 2012 | 116 | 0.490 |
Why?
|
| Dermatologic Agents | 2 | 2016 | 22 | 0.470 |
Why?
|
| Benchmarking | 1 | 2016 | 137 | 0.440 |
Why?
|
| Pregnancy Complications | 2 | 2011 | 381 | 0.420 |
Why?
|
| Medical Errors | 1 | 2016 | 198 | 0.420 |
Why?
|
| Rhinoplasty | 1 | 2012 | 10 | 0.370 |
Why?
|
| Isotretinoin | 1 | 2011 | 2 | 0.350 |
Why?
|
| Abnormalities, Drug-Induced | 1 | 2011 | 14 | 0.350 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2011 | 48 | 0.340 |
Why?
|
| Dermatology | 3 | 2019 | 65 | 0.340 |
Why?
|
| Mentors | 1 | 2012 | 119 | 0.340 |
Why?
|
| Postoperative Hemorrhage | 1 | 2011 | 40 | 0.340 |
Why?
|
| Skin Diseases | 2 | 2016 | 80 | 0.330 |
Why?
|
| Interprofessional Relations | 1 | 2012 | 137 | 0.330 |
Why?
|
| Scalp | 2 | 2006 | 29 | 0.310 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2011 | 233 | 0.300 |
Why?
|
| Carcinoma, Verrucous | 1 | 2006 | 3 | 0.250 |
Why?
|
| Anticoagulants | 1 | 2011 | 522 | 0.250 |
Why?
|
| Dermatitis, Contact | 1 | 2006 | 12 | 0.250 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2016 | 372 | 0.250 |
Why?
|
| Surgical Instruments | 1 | 2005 | 44 | 0.230 |
Why?
|
| Plants, Medicinal | 1 | 2005 | 19 | 0.230 |
Why?
|
| Head and Neck Neoplasms | 1 | 2006 | 164 | 0.230 |
Why?
|
| Phytotherapy | 1 | 2005 | 34 | 0.230 |
Why?
|
| Terminology as Topic | 1 | 2006 | 144 | 0.220 |
Why?
|
| Humans | 22 | 2022 | 64768 | 0.220 |
Why?
|
| Postoperative Complications | 1 | 2011 | 1313 | 0.210 |
Why?
|
| Hemostasis, Surgical | 1 | 2022 | 21 | 0.180 |
Why?
|
| Needlestick Injuries | 1 | 2002 | 19 | 0.180 |
Why?
|
| Needles | 1 | 2002 | 64 | 0.170 |
Why?
|
| Nose | 3 | 2010 | 27 | 0.160 |
Why?
|
| Efficiency | 1 | 2019 | 39 | 0.150 |
Why?
|
| Drug Prescriptions | 1 | 2019 | 164 | 0.140 |
Why?
|
| Vitiligo | 1 | 2019 | 120 | 0.120 |
Why?
|
| Female | 10 | 2019 | 33804 | 0.120 |
Why?
|
| Insurance, Pharmaceutical Services | 1 | 2016 | 17 | 0.120 |
Why?
|
| Pharmaceutical Services | 1 | 2016 | 33 | 0.120 |
Why?
|
| Drug Costs | 1 | 2016 | 55 | 0.120 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2016 | 260 | 0.120 |
Why?
|
| Patient Satisfaction | 1 | 2019 | 434 | 0.120 |
Why?
|
| United States Food and Drug Administration | 2 | 2016 | 90 | 0.110 |
Why?
|
| Nail Diseases | 1 | 2016 | 49 | 0.110 |
Why?
|
| Delivery of Health Care | 1 | 2019 | 432 | 0.110 |
Why?
|
| Preoperative Care | 1 | 2016 | 198 | 0.110 |
Why?
|
| Analgesics, Opioid | 1 | 2019 | 525 | 0.110 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2019 | 705 | 0.100 |
Why?
|
| Equipment Design | 2 | 2005 | 360 | 0.090 |
Why?
|
| Achievement | 1 | 2012 | 29 | 0.090 |
Why?
|
| Pregnancy | 2 | 2011 | 2362 | 0.090 |
Why?
|
| Ticlopidine | 1 | 2011 | 47 | 0.090 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2011 | 57 | 0.080 |
Why?
|
| Device Approval | 1 | 2011 | 13 | 0.080 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2011 | 49 | 0.080 |
Why?
|
| Melanoma, Amelanotic | 1 | 2010 | 2 | 0.080 |
Why?
|
| Necrosis | 1 | 2011 | 148 | 0.080 |
Why?
|
| Hutchinson's Melanotic Freckle | 1 | 2010 | 5 | 0.080 |
Why?
|
| Aminoquinolines | 1 | 2010 | 16 | 0.080 |
Why?
|
| Sunbathing | 1 | 2011 | 31 | 0.080 |
Why?
|
| Warfarin | 1 | 2011 | 124 | 0.080 |
Why?
|
| Program Development | 1 | 2011 | 208 | 0.080 |
Why?
|
| Surgical Wound Infection | 1 | 2011 | 124 | 0.080 |
Why?
|
| Aged | 4 | 2019 | 14882 | 0.080 |
Why?
|
| Nose Diseases | 1 | 2009 | 7 | 0.080 |
Why?
|
| Ultraviolet Rays | 1 | 2011 | 146 | 0.080 |
Why?
|
| Male | 6 | 2019 | 30840 | 0.080 |
Why?
|
| Program Evaluation | 1 | 2011 | 488 | 0.070 |
Why?
|
| Melanoma | 1 | 2011 | 332 | 0.060 |
Why?
|
| Papillomaviridae | 1 | 2006 | 59 | 0.060 |
Why?
|
| Cosmetics | 1 | 2006 | 16 | 0.060 |
Why?
|
| Anesthetics | 1 | 2006 | 13 | 0.060 |
Why?
|
| Syphilis | 1 | 2006 | 25 | 0.060 |
Why?
|
| Aged, 80 and over | 2 | 2016 | 5590 | 0.060 |
Why?
|
| Europe | 1 | 2006 | 197 | 0.060 |
Why?
|
| Endarterectomy | 1 | 2005 | 16 | 0.060 |
Why?
|
| Trifolium | 1 | 2005 | 2 | 0.060 |
Why?
|
| Sanguinaria | 1 | 2005 | 2 | 0.060 |
Why?
|
| Rumex | 1 | 2005 | 2 | 0.060 |
Why?
|
| Ointments | 1 | 2005 | 7 | 0.060 |
Why?
|
| Cheek | 1 | 2005 | 5 | 0.060 |
Why?
|
| Postoperative Care | 1 | 2006 | 125 | 0.060 |
Why?
|
| Analgesics | 1 | 2006 | 102 | 0.060 |
Why?
|
| Perioperative Care | 1 | 2006 | 86 | 0.060 |
Why?
|
| Treatment Failure | 1 | 2005 | 206 | 0.060 |
Why?
|
| Complementary Therapies | 1 | 2005 | 63 | 0.050 |
Why?
|
| United States | 3 | 2016 | 8052 | 0.050 |
Why?
|
| Risk Factors | 3 | 2016 | 5392 | 0.050 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2002 | 13 | 0.050 |
Why?
|
| Equipment Safety | 1 | 2002 | 26 | 0.040 |
Why?
|
| Neoplasm, Residual | 1 | 2002 | 50 | 0.040 |
Why?
|
| Device Removal | 1 | 2002 | 64 | 0.040 |
Why?
|
| Middle Aged | 4 | 2019 | 18156 | 0.040 |
Why?
|
| Reoperation | 1 | 2002 | 300 | 0.040 |
Why?
|
| Surgical Procedures, Operative | 1 | 2002 | 141 | 0.040 |
Why?
|
| Adult | 3 | 2019 | 17251 | 0.040 |
Why?
|
| Anti-Bacterial Agents | 1 | 2006 | 795 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2002 | 1159 | 0.040 |
Why?
|
| Retrospective Studies | 2 | 2016 | 6818 | 0.030 |
Why?
|
| Drugs, Generic | 1 | 2016 | 19 | 0.030 |
Why?
|
| Delayed Diagnosis | 1 | 2016 | 47 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2019 | 734 | 0.030 |
Why?
|
| Needs Assessment | 1 | 2016 | 201 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2016 | 221 | 0.030 |
Why?
|
| Health Expenditures | 1 | 2016 | 121 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2019 | 2042 | 0.020 |
Why?
|
| Medicaid | 1 | 2016 | 361 | 0.020 |
Why?
|
| Medicare | 1 | 2016 | 619 | 0.020 |
Why?
|
| Beauty Culture | 1 | 2011 | 16 | 0.020 |
Why?
|
| Administration, Topical | 1 | 2010 | 50 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 2010 | 134 | 0.020 |
Why?
|
| Child | 1 | 2019 | 4554 | 0.020 |
Why?
|
| Young Adult | 1 | 2019 | 4772 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2010 | 895 | 0.020 |
Why?
|
| Adolescent | 1 | 2019 | 6247 | 0.020 |
Why?
|
| Treatment Outcome | 2 | 2010 | 5765 | 0.020 |
Why?
|
| Esthetics | 1 | 2006 | 18 | 0.020 |
Why?
|
| Incidence | 1 | 2011 | 1410 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2010 | 2473 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2010 | 2090 | 0.010 |
Why?
|